Xintela AB (FRA:1XT) Moat Score: 0/10 (As of Jul. 05, 2026)


FRA:1XT Xintela AB FRA:1XT
8 GF Score
Price €0.01
! 2 Warning Signs
View Full Analysis

What is Xintela AB Moat Score?

Xintela AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Xintela AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Xintela AB might have No Moat - No discernible moat.

Xintela AB  (FRA:1XT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Xintela AB Moat Score Related Terms

FRA:1XT
8GF Score
Xintela AB FRA:1XT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xintela AB Business Description

Other Exchanges XINT:Sweden
Address Medicon Village, Lund, SWE, 223 81
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score

Get the complete analysis for FRA:1XT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price